Ampio Pharmaceuticals Inc (AMPE)

[dude iligence]

AMPE .96 Article with paragraph about AMPE

ARTHRITIS

Drug companies initially figured out that blocking certain cytokines might be beneficial. Arthritis drugs like Actemra® manufactured by Roche Holdings (OTCMKTS: RBBHY) and Kevzara® a joint venture manufactured by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) were used to target the IL-6 cytokine which is elevated in COVID-19. In August Roche announced that Actemra failed to meet its endpoint in COVID-19. Almost a month later in early September Kevzara announced that it failed as well. The only arthritis drug left in the space is Ampio Pharmaceuticals (NASDAQ: AMPE). It recently completed a phase 1 study with great results. In a proof of concept study IV use of the drug was extremely well tolerated with no adverse events and showed a greater improvement over the standard of care, which had one death and one hospitalization which represented 40% of the small cohort. In the active arm all severe patients were discharged in 5 days. The FDA quickly approved a phase 2 study for inhaled use of Ampion®. What is different about Ampion® is that it targets many inflammatory cytokines like (TNFa, IL-1ß, IL-6, IL-12) and not just IL-6.

https://emerginggrowth.com/galectin-therapeutics-galt-is-due-for-a-covid-19-makeover/






well defined up channel resistance .99-.100 pressure building for sustained move above $1.